AI Article Synopsis

  • Treatment of psychosomatic disorders requires medication alongside psychotherapy for effective outcomes.
  • A study involved 90 adolescents with psychosomatic issues, divided into two groups, one receiving medication alone and the other receiving medication with psychotherapy.
  • Results showed that both treatment approaches led to a significant decrease in anxiety levels and improved self-expression, with combined treatment showing particularly positive effects on cognitive activity.

Article Abstract

Treatment of psychosomatic disorders does not allow to do without medication intervention, although psychotherapy is important, aimed at correcting psychopathological symptoms. That's why, the definition of a method of therapy, which is better and more likely to cause positive results. The aim - determining which the better method of treatment and more effective of the causes a positive shift in the dynamics of clinical syndromes. The group of 90 adolescents (34 boys and 56 girls) with psychosomatic disorders divided into 2 groups, were inspected using received comprehensive clinical psychopathological examination. The average age of adolescents was 14.4 ± 0.06 years old. The 1-st group (57 persons) consisted of adolescents, who received treatment with Lamotrigine and Sertraline 25 mg / day for persons from 12 to 16 years old and 50 mg / day - over 16 years old. The duration of treatment was 1.5-2 months. Adolescents of the 2-nd group (33 persons) were prescribed Lamotrigine and Sertraline therapy in combination with psychotherapy. Control of therapeutic effectiveness was evaluated by clinical and Spielberger anxiety questionnaire (STPI - State Trait Personal Inventory), Phillips' school anxiety test and CDI scale (Children Depression's Inventory) by M. Kovacs. Statistical processing was carried out on the basis of the computer program "Statistica 6.1." (Stat Soft Inc., USA). The anxiety level moved to an average level after medication, except situational negative experiences, which remained at a high level. In adolescents of the 1-st and 2-nd groups the fear of self-expression decreased significantly by comparison with it before treatment. The anxiety test scores decreased to an average level after complex treatment. At the same time the level of personal cognitive activity remained high, which confirmed the positive effect of combined treatment of psychosomatic disorders due to increased interest, curiosity, interest, which activates cognitive activity of adolescents. The level of depression in the 1-st group of adolescents after the treatment was 2.16 ± 0.16, which corresponded to the level of subdepression or masked depression with high scores on scale B. On the background of combined treatment in adolescents the level of depression decreased to 1.71 ± 0.12, which corresponded to slight decrease of mood with high scores on scale B. Adolescents with psychosomatic disorders who responded positively to psychotherapy were characterized by low level of somatization, but higher specific weight of psychological problems and difficulties in interpersonal relationships in the internal picture of the illness with peaks at subclasses of interpersonal sensitivity and hostility. The obtained results of treatment of psychosomatic disorders in adolescents show positive influence of both methods of therapy. However, adolescents with psychosomatic disorders were most susceptible to complex treatment, which accelerates the regression of clinical manifestations and increases the effectiveness of treatment 2.85 times.

Download full-text PDF

Source

Publication Analysis

Top Keywords

psychosomatic disorders
24
treatment
13
complex treatment
12
adolescents
12
adolescents psychosomatic
12
treatment psychosomatic
12
level
9
treatment adolescents
8
group adolescents
8
1-st group
8

Similar Publications

Background: Subjective cognitive decline (SCD), in the absence of objective cognitive impairment, may be the first symptomatic manifestation of Alzheimer's disease (AD). Previous studies have suggested that its combination with amyloid-positivity (Aβ+) may represent stage 2 AD, and is associated with a higher risk of future cognitive decline. Here, we aim to (1) confirm this using the plasma Aβ42/40 ratio, and (2) test whether the addition of plasma phospho-tau181 (ptau, a marker of Aβ and tau pathology) could help refine the prediction of future cognitive decline in SCD patients.

View Article and Find Full Text PDF

Relationship Between ABO Blood Groups and Mental Disorders.

J Blood Med

January 2025

Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Previous research has unveiled an intriguing positive association between the AB blood group and mental disorders in general. In this study, we compared ABO blood groups with five major groups of mental disorders to attain a higher level of specificity. The analyses were conducted using data from the CoLaus|PsyCoLaus study (N=5111).

View Article and Find Full Text PDF

Objective: Individuals with low socioeconomic status (SES) exhibit higher rates of mental disorders; however, data in oncological populations are insufficient. This study investigated the course of DSM-5 mental disorders in cancer patients, stratified by SES, over a period of 1.5 years following initial cancer diagnosis.

View Article and Find Full Text PDF

Background: In humans, environmental enrichment (EE), as measured by the engagement in a variety of leisure activities, has been associated with larger hippocampal structure and better memory function. The present cross-sectional study assessed whether EE during early life (13-30 years) and midlife (30-65 years) is associated with better preserved memory-related brain activity patterns in older age.

Methods: In total, 372 cognitively unimpaired older adults (aged ≥60 years old) of the DZNE-Longitudinal Study on Cognitive Impairment and Dementia (DELCODE; DRKS00007966) were investigated.

View Article and Find Full Text PDF

Background: Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This traditional Amazonian plant decoction contains N,N-dimethyltryptamine (DMT) and β-carboline alkaloids such as harmine. However, its use is often accompanied by distressing effects like nausea, vomiting, and intense hallucinations, possibly due to complex pharmacokinetic/pharmacodynamic (PK-PD) interactions and lack of dose standardization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!